Genetic determinants of cell type-specific poliovirus propagation in HEK 293 cells

Journal of Virology

Volumn 79, Issue 10, 2005, Pages 6281-6290

  Campbell, Stephanie A ^a   Lin, Jennifer ^a   Dobrikova, Elena Y ^a   Gromeier, Matthias ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL STRAIN HEK293; CELL TYPE; EMBRYO; GENE MUTATION; GENE SEQUENCE; GENE STRUCTURE; HUMAN; HUMAN CELL; HUMAN RHINOVIRUS; INTERNAL RIBOSOME ENTRY SITE; NERVE CELL; NUCLEOTIDE SEQUENCE; PHENOTYPE; POINT MUTATION; POLIOMYELITIS SABIN VIRUS; POLIOMYELITIS VIRUS; POLIOMYELITIS VIRUS 1; PRIORITY JOURNAL; PROTEIN DOMAIN; VIROGENESIS; VIRUS GENOME; VIRUS PATHOGENESIS; VIRUS RECOMBINATION; VIRUS REPLICATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; CELL LINE, TRANSFORMED; HUMANS; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; POLIOVIRUS; REASSORTANT VIRUSES; RHINOVIRUS; SPECIES SPECIFICITY; VIRULENCE; VIRUS REPLICATION;

ANIMALIA; HUMAN RHINOVIRUS SP.; POLIOVIRUS;

EID: 18144416539     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.10.6281-6290.2005     Document Type: Article

References (62)

1. Agol, V. I., S. G. Drozdov, T. A. Ivannikova, M. S. Kolesnikova, M. B. Korolev, and E. A. Tolskaya. 1989. Restricted growth of attenuated poliovirus strains in cultured cells of a human neuroblastoma. J. Virol. 63:4034-4038.
2. Barton, D. J., B. J. O'Donnell, and J. B. Flanegan. 2001. 5′ cloverleaf in poliovirus RNA is a cis-acting replication element required for negative-strand synthesis. EMBO J. 20:1439-1448.
3. Bergamini, G., T. Preiss, and M. W. Hentze. 2000. Picornavirus IRESes and the poly(A) tail jointly promote cap-independent translation in a mammalian cell-free system. RNA 6:1781-1790.
4. Bodian, D. 1972. Poliomyelitis, p. 2323-2343. In J. Minckler (ed.), Pathology of the nervous system. McGraw-Hill, New York, N.Y.
5. Borman, A. M., F. G. Deliat, and K. M. Kean. 1994. Sequences within the poliovirus internal ribosome entry segment control viral RNA synthesis. EMBO J. 13:3149-3157.
6. Cherkasova, E., M. Laassri, V. Chizhikov, E. Korotkova, E. Dragunsky, V. I. Agol, and K. Chumakov. 2003. Microarray analysis of evolution of RNA viruses: evidence of circulation of virulent highly divergent vaccine-derived polioviruses. Proc. Natl. Acad. Sci. USA 100:9398-9403.
7. Chezzi, C., C. J. Dommann, N. K. Blackburn, E. Maselesele, J. McAnerney, and B. D. Schoub. 1998. Genetic stability of oral polio vaccine prepared on primary monkey kidney cells or Vero cells-effects of passage in cell culture and the human gastrointestinal tract. Vaccine 16:2031-2038.
8. Christodoulou, C., F. Colbere-Garapin, A. Macadam, L. F. Taffs, S. Marsden, P. Minor, and F. Horaud. 1990. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J. Virol. 64:4922-4929.
9. Dobrikova, E., P. Florez, S. Bradrick, and M. Gromeier. 2003. Activity of a type 1 picornavirus internal ribosomal entry site is determined by sequences within the 3′ non-translated region. Proc. Natl. Acad. Sci. USA 100:15125-15130.
10. Dobrikova, E. Y., P. Florez, and M. Gromeier. 2003. Structural determinants of insert retention of poliovirus expression vectors with recombinant IRES elements. Virology 311:241-253.
11. Dragunsky, E., T. Nomura, K. Karpinski, J. Furesz, D. J. Wood, Y. Pervikov, S. Abe, T. Kurata, O. Vanloocke, G. Karganova, R. Taffs, A. Heath, A. Ivshina, and I. Levenbook. 2003. Transgenic mice as an alternative to monkeys for neurovirulence testing of live oral poliovirus vaccine: validation by a W.H.O. collaborative study. Bull. W. H. O. 81:251-260.
12. Dufresne, A. T., E. Y. Dobrikova, S. Schmidt, and M. Gromeier. 2002. Genetically stable picornavirus expression vectors with recombinant internal ribosomal entry sites. J. Virol. 76:8966-8972.
13. Evans, D. M. A., G. Dunn, P. D. Minor, G. C. Schild, A. J. Cann, G. Stanway, J. W. Almond, K. Currey, and J. V. Maizel. 1985. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature 314:548-550.
14. Gmyl, A. P., E. V. Pilipenko, S. V. Maslova, G. A. Belov, and V. I. Agol. 1993. Functional and genetic plasticities of the poliovirus genome: quasi-infectious RNAs modified in the 5′-untranslated region yield a variety of pseudorevertants. J. Virol. 67:6309-6316.
15. Graham, F. L., J. Smiley, W. C. Russell, and R. Nairn. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59-74.
16. Gromeier, M., and A. Nomoto. 2002. Determinants of poliovirus pathogenesis, p. 367-379. In B. Semler and E. Wimmer (ed.), Molecular biology of picornaviruses. ASM Press, Washington, D.C.
17. Gromeier, M., S. Lachmann, M. Rosenfeld, P. H. Gutin, and E. Wimmer. 2000. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl. Acad. Sci. USA 97:6803-6808.
18. Gromeier, M., B. Bossert, M. Arita, A. Nomoto, and E. Wimmer. 1999. Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence. J. Virol. 73:958-964.
19. Gromeier, M., L. Alexander, and E. Wimmer. 1996. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc. Natl. Acad. Sci. USA 93:2370-2375.
20. Guillot, S., D. Otelea, F. Delpeyroux, and R. Crainic. 1994. Point mutations involved in the attenuation/neurovirulence alternation in type 1 and 2 oral polio vaccine strains detected by site-specific polymerase chain reaction. Vaccine 12:503-507.
21. Haller, A. A., S. R. Stewart, and B. L. Semler. 1996. Attenuation stem-loop lesions in the 5′ noncoding region of poliovirus RNA: neuronal cell-specific translation defects. J. Virol. 70:1467-1474.
22. Haller, A. A., and B. L. Semler. 1995. Stem-loop structure synergy in binding cellular proteins to the 5′ noncoding region of poliovirus RNA. Virology 206:923-934.
23. Herold, J., and R. Andino. 2001. Poliovirus RNA replication requires genome circularization through a protein-protein bridge. Mol. Cell 7:581-591.
24. Hunt, S. L., and R. J. Jackson. 1999. Polypyrimidine-tract binding protein (PTB) is necessary, but not sufficient, for efficient internal initiation of translation of human rhinovirus-2 RNA. RNA 5:344-359.
25. Hunt, S. L., J. J. Hsuan, N. Totty, and R. J. Jackson. 1999. Unr, a cellular cytoplasmic RNA-binding protein with five cold-shock domains, is required for internal initiation of translation of human rhinovirus RNA. Genes Dev. 13:437-448.
26. Iizuka, N., M. Kohara, K. Hagino-Yamagishi, S. Abe, T. Komatsu, K. Tago, M. Arita, and A. Nomoto. 1989. Construction of less neurovirulent polioviruses by introducing deletions into the 5′ noncoding sequence of the genome. J. Virol. 63:5354-5363.
27. Jang, S. K., H. G. Kräusslich, M. J. H. Nicklin, G. M. Duke, A. C. Palmenberg, and E. Wimmer. 1988. A segment of the 5′ nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J. Virol. 62:2636-2643.
28. Katsetos, C. D., M. M. Herman, and S. J. Mork. 2003. Class III beta-tubulin in human development and cancer. Cell Motil. Cytoskelet. 55:77-96.
29. Kawamura, N., M. Kohara, S. Abe, T. Komats, K. Tago, M. Arita, and A. Nomoto. 1989. Determinants in the 5′ noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J. Virol. 63:1302-1309.
30. Kitamura, N., B. L. Semler, P. G. Rothberg, G. R. Larsen, C. J. Adler, A. J. Dorner, E. A. Emini, R. Hanecak, J. J. Lee, S. van der Werf, C. W. Anderson, and E. Wimmer. 1981. Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature 291:547-553.
31. Kuge, S., and A. Nomoto. 1987. Construction of viable deletion and insertion mutants of the Sabin strain of type 1 poliovirus: function of the 5′ noncoding sequence in viral replication. J. Virol. 61:1478-1487.
32. La Monica, N., and V. R. Racaniello. 1989. Differences in replication of attenuated and neurovirulent polioviruses in human neuroblastoma cell line SH-SY5Y. J. Virol. 63:2357-2360.
33. Lee, M. K., and D. W. Cleveland. 1996. Neuronal intermediate filaments. Annu. Rev. Neurosci. 19:187-217.
34. Macadam, A. J., S. R. Pollard, G. Ferguson, R. Skuce, D. Wood, J. W. Almond, and P. D. Minor. 1993. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 192:18-26.
35. Macadam, A. J., G. Ferguson, J. Burlison, D. Stone, R. Skuce, J. W. Almond, and P. D. Minor. 1992. Correlation of RNA secondary structure and attenuation of Sabin vaccine strains of poliovirus in tissue culture. Virology 189:415-422.
36. Markovtsov, V., J. M. Nikolic, J. A. Goldman, C. W. Turck, M. Y. Chou, and D. L. Black. 2000. Cooperative assembly of an hnRNP complex induced by a tissue-specific homolog of polypyrimidine tract binding protein. Mol. Cell. Biol. 20:7463-7479.
37. Murray, K. E., B. P. Steil, A. W. Roberts, and D. J. Barton. 2004. Replication of poliovirus RNA with complete internal ribosome entry site deletions. J. Virol. 78:1393-1402.
38. Nomoto, A., T. Omata, H. Toyoda, S. Kuge, H. Horie, Y. Kataoka, Y. Genba, Y. Nakano, and N. Imura. 1982. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proc. Natl. Acad. Sci. USA 79:5793-5797.
39. Ochs, K., A. Zeller, L. Saleh, G. Bassili, Y. Song, A. Sonntag, and M. Niepmann. 2003. Impaired binding of standard initiation factors mediates poliovirus translation attenuation. J. Virol. 77:115-122.
40. Ohka, S., and A. Nomoto. 2001. The molecular basis of poliovirus neurovirulence. Dev. Biol. 105:51-58.
41. Paul, A. V., J. Mugavero, J. Yin, S. Hobson, S. Schultz, J. H. van Boom, and E. Wimmer. 2000. Studies on the attenuation phenotype of polio vaccines: poliovirus RNA polymerase derived from Sabin type 1 sequence is temperature sensitive in the uridylylation of VPg. Virology 272:72-84.
42. Pelletier, J., and N. Sonenberg. 1988. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 334:320-325.
43. Pilipenko, E. V., A. P. Gmyl, S. V. Maslova, Y. V. Svitkin, A. N. Sinyakov, and V. I. Agol. 1992. Prokaryotic-like cis elements in the cap-independent internal initiation of translation on picornavirus RNA. Cell 68:119-131.
44. Pilipenko, E. V., E. G. Viktorova, S. T. Guest, V. I. Agol, and R. P. Roos. 2001. Cell-specific proteins regulate viral RNA translation and virus-induced disease. EMBO J. 20:6899-6908.
45. Ren, R. B., F. Costantini, E. J. Gorgacz, J. J. Lee, and V. R. Racaniello. 1990. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell 63:353-362.
46. Rettig, W. J., B. A. Spengler, P. G. Chesa, L. J. Old, and J. L. Biedler. 1987. Coordinate changes in neuronal phenotype and surface antigen expression in human neuroblastoma cell variants. Cancer Res. 47:1383-1389.
47. Ross, R. A., B. A. Spengler, and J. L. Biedler. 1983. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J. Nat. Cancer Inst. 71:741-749.
48. Sabin, A. B. 1965. Oral poliovirus vaccine. History of its development and prospects for eradication of poliomyelitis. JAMA 194:872-876.
49. Semler, B. 2004. Poliovirus proves IRES-istible in vivo. J. Clin. Investig. 113:1678-1681.
50. Shaw, G., S. Morse, M. Ararat, and F. L. Graham. 2002. Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J. 16:869-871.
51. Skinner, M. A., V. R. Racaniello, G. Dunn, J. Cooper, P. D. Minor, and J. W. Almond. 1989. New model for the secondary structure of the 5′ non-coding RNA of poliovirus is supported by biochemical and genetic data that also show that RNA secondary structure is important in neurovirulence. J. Mol. Biol. 207:379-392.
52. Stanway, G., P. J. Hughes, R. C. Mountford, P. Reeve, P. D. Minor, G. C. Schild, and J. W. Almond. 1984. Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12alb. Proc. Natl. Acad. Sci. USA 81:1539-1543.
53. Stanway, G., A. J. Cann, R. Hauptmann, P. Hughes, L. D. Clarke, R. C. Mountford, P. D. Minor, G. C. Schild, and J. W. Almond. 1983. The nucleotide sequence of poliovirus type 3 Leon 12 alb: comparison with poliovirus type 1. Nucleic Acids Res. 11:5629-5643.
54. Svitkin, Y. V., H. Imataka, K. Khaleghpour, A. Kahvejian, H. D. Liebig, and N. Sonenberg. 2001. Poly(A)-binding protein interaction with elF4G stimulates picornavirus IRES-dependent translation. RNA 7:1743-1752.
55. Svitkin, Y. V., N. Cammack, P. D. Minor, and J. W. Almond. 1990. Translation deficiency of the Sabin type 3 poliovirus genome: association with an attenuating mutation C472→U. Virology 175:103-109.
56. Toyoda, H., M. Kohara, Y. Kataoka, T. Suganuma, T. Omata, N. Imura, and A. Nomoto. 1984. Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants. J. Mol. Biol. 174:561-585.
57. Walter, B. L., J. H. Nguyen, E. Ehrenfeld, and B. Semler. 1999. Differential utilization of poly(rC) binding protein 2 in translation directed by picornavirus IRES elements. RNA 5:1570-1585.
58. Weeks-Levy, C., J. M. Tatem, S. J. DiMichele, W. Waterfield, A. F. Georgiu, and S. J. Mento. 1991. Identification and characterization of a new base substitution in the vaccine strain of Sabin 3 poliovirus. Virology 185:934-937.
59. Westrop, G. D., K. A. Wareham, D. M. Evans, G. Dunn, P. D. Minor, D. I. Magrath, F. Taffs, S. Marsden, M. A. Skinner, G. C. Schild, and J. W. Almond. 1989. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J. Virol. 63:1338-1344.
60. W.H.O. Collaborative Study Group. 1982. The relationship between persisting spinal paralysis and poliomyelitis vaccine-results of a ten-year inquiry. Bull. W. H. O. 60:231-242.
61. Wimmer, E., C. U. T. Hellen, and X. Cao. 1983. Genetics of poliovirus. Annu. Rev. Genet. 27:353-436.
62. Wood, D. J., R. W. Sutter, and W. R. Dowdle. 2000. Stopping poliovirus vaccination after eradication: issues and challenges. Bull. W. H. O. 78:347-357.